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ABSTRACT
Understanding the mechanisms of cancer therapeutic resistance is
fundamental to improving cancer care. There is clear benefit
from chemotherapy in different breast cancer settings; however,
knowledge of the mutations and genes that mediate resistance is
incomplete. In this study, by modeling chemoresistance in patient-
derived xenografts (PDXs), we show that adaptation to therapy is
genetically complex and identify that loss of transcription factor 4
(TCF4; also known as ITF2) is associated with this process. A triple-
negative BRCA1-mutated PDX was used to study the genetics
of chemoresistance. The PDX was treated in parallel with four
chemotherapies for five iterative cycles. Exome sequencing identified
few genes with de novo or enriched mutations in common among the
different therapies, whereas many common depleted mutations/
genes were observed. Analysis of somatic mutations from The
Cancer Genome Atlas (TCGA) supported the prognostic relevance of
the identified genes. A mutation in TCF4 was found de novo in all
treatments, and analysis of drug sensitivity profiles across cancer cell
lines supported the link to chemoresistance. Loss of TCF4 conferred
chemoresistance in breast cancer cell models, possibly by altering
cell cycle regulation. Targeted sequencing in chemoresistant tumors
identified an intronic variant of TCF4 that may represent an
expression quantitative trait locus associated with relapse outcome
in TCGA. Immunohistochemical studies suggest a common loss of
nuclear TCF4 expression post-chemotherapy. Together, these
results from tumor xenograft modeling depict a link between altered
TCF4 expression and breast cancer chemoresistance.
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INTRODUCTION
Triple-negative breast cancer (TNBC), defined by the absence (or
relative low expression) of the estrogen and progesterone receptors (ER
and PR, respectively) and of human epidermal growth factor receptor 2
(HER2), accounts for 15-20% of all breast cancer cases (Foulkes et al.,
2010). The lack of the defined molecular markers means that the
standard targeted treatments currently available for other settings (i.e.
endocrine-based or anti-HER2 therapy) are inapplicable. Conventional
chemotherapy – CMF (cyclophosphamide, methotrexate and
fluorouracil) and/or anthracycline- and taxane-containing regimens –
is the basis ofTNBC treatment according to themajorityof national and
international guidelines (Coates et al., 2015). These therapies typically
give response rates of 30-70%, but they are often not durable, with a
time to progression of 6-10 months (vonMinckwitz et al., 2012). In this
context, resistancemayarise through anumberof differentmechanisms
(O’Reilly et al., 2015) and tumor cell heterogeneity coupled with high
mutation rates may be a key factor contributing to a rapid selection of
drug-resistant clones (de Bruin et al., 2013).
Given the clinical impact of therapeutic resistance, there is
renewed interest in platinum-based drugs, either as a single agent or
in combination therapy. This interest is principally led by the high
frequency of germline and/or somatic alterations in the BRCA1 gene
in TNBC tumors (Silver et al., 2010). However, addition of
platinums in therapy increases toxicity and, most importantly, there
is no conclusive evidence that these agents improve disease-free and
overall survival (La Belle et al., 2017). Based on the same idea of
specific vulnerabilities, alteration of DNA repair signaling is also
being assessed as a therapeutic approach using, for example, poly-
ADP ribose polymerase (PARP) inhibitors (Lord and Ashworth,
2013; La Belle et al., 2017). Nevertheless, chemotherapy is
generally applied empirically, with no validated test or biomarker
to reliably predict response to or benefit from a particular regime
(Caponigro and Sellers, 2011). In this scenario, PDXs have proven
to be an effective approach for the assessment of novel therapeutic
approaches and are widely used in preclinical drug development
(Byrne et al., 2017). PDXs provide the opportunity to place the
same patient tumor under a battery of therapeutic regimens and,
thus, identify useful vulnerabilities. At the same time, PDXs
facilitate the study of human tumor-specific characteristics. In this
study, PDX-based modeling of breast cancer chemoresistance leadsReceived 29 September 2017; Accepted 10 April 2018
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Oncologıá del Principado de Asturias, Universidad de Oviedo, Oviedo 33006,
Spain. 4Hereditary Cancer Programme, ICO, Oncobell, IDIBELL, L’Hospitalet del
Llobregat, Barcelona 08908, Catalonia, Spain. 5Chemoresistance and Predictive
Factors Laboratory, ProCURE, ICO, Oncobell, IDIBELL, L’Hospitalet del Llobregat,
Barcelona 08908, Catalonia, Spain. 6Departments of Clinical Science and Internal
Medicine, Haematology Section, Haukeland University Hospital, and Centre for
Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen,
Bergen 5021, Norway. 7Department of Pathology, University Hospital of Bellvitge,
Oncobell, IDIBELL, L’Hospitalet del Llobregat, Barcelona 08908, Catalonia, Spain.
8Biomedical Research Networking Centre of Cancer, CIBERONC, Spain. 9Xenopat
S.L., Business Bioincubator, Bellvitge Health Science Campus, L’Hospitalet del
Llobregat, Barcelona 08908, Catalonia, Spain.
*Author for correspondence (mapujana@iconcologia.net)
M.A.P., 0000-0003-3222-4044
This is an Open Access article distributed under the terms of the Creative Commons Attribution
License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution and reproduction in any medium provided that the original work is properly attributed.
1
© 2018. Published by The Company of Biologists Ltd | Disease Models & Mechanisms (2018) 11, dmm032292. doi:10.1242/dmm.032292
D
is
ea
se
M
o
d
el
s
&
M
ec
h
an
is
m
s
to the identification of loss of TCF4 as being associated with this
phenotype.
RESULTS
Adaptation to chemotherapy
A breast tumor from a 33-year-old woman carrying a pathological
germline BRCA1 mutation (c.302-1G>A) was obtained at surgery
and subsequently engrafted in the mammary fat pad of female
athymic mice. The patient had received four cycles of TAC
(docetaxel, doxorubicin and cyclophosphamide) regimen at the
time of surgery, but with no substantial clinical or pathological
responses. The PDX was established for three passages before
chemoresistance modeling was initiated. Next, replicates of the
PDX were treated in parallel with cisplatin (a platinum-containing
drug), fluorouracil (an anti-metabolite and irreversible inhibitor of
thymidylate synthase), lurbinectedin (a DNA minor-groove binder)
or olaparib (a PARP inhibitor). Five treatment cycles were applied,
consisting of approximately 3 weeks of drug administration
followed by surgery for tumor removal (Fig. 1A). Recapitulating
what is commonly observed in the emergence of therapeutic
resistance, the required time to relapse (defined as tumors with a
volume of 500-750 mm3) fell in parallel with the number of
treatment cycles (Fig. 1B). This trend was observed in the four drug
settings, indicating that the tumors were adapted to chemotherapy.
None of the treated PDXs showed reversion to wild-type status of
the germline BRCA1 mutation (Fig. S1). Thus, in vivo adaptation to
the chemotherapies could be partially mediated by the acquisition of
additional genetic alterations.
Genetic heterogeneity linked to chemoresistance
To investigate the genetics of chemoresistance, exome sequences
were obtained at an average coverage >80× for each of the four
adapted chemotherapeutic settings, the parental PDX and germline
samples. In total, 187 mutations were identified relative to the
germline genome of the patient: six frameshift, seven nonsense, one
affecting a consensus splice site and 173 missense. Sixty-four
mutations were considered de novo since they were absent from the
parental PDX at the defined exome coverage (Table S1). Forty-three
mutations were completely depleted in at least one of the adapted
models (Table S2), and 80 mutations were present in both the
adapted and parental settings relative to the germline. Among the
latter, 22 and 19 were significantly enriched (Table S3) and depleted
(Table S2), respectively, in at least one of the chemoresistance
models. To assess the validity of mutation calls, 21 changes were
selected for Sanger-based sequence analysis; these included six
frameshift and 15 point mutations (six nonsense, eight missense and
one splice site). Only two of the predicted mutations, including a
frameshift mutation, were not validated (Table S4). To further assess
the validity of somatic mutations and precisely determine their
frequencies, 20 of these changes were analyzed by deep-targeted
sequencing in seven DNA samples from the same study case: from
the germline, primary tumor, parental xenograft and each of the
resistant xenograft models (mean coverage 8223-fold). This
analysis corroborated the somatic acquisition of the mutations and
expanded the identification of three of themwith >10% frequency in
the olaparib-resistant xenograft (Table S5). The fact that these three
mutations were not initially identified in the sample used for exome
and Sanger sequencing, but detected in a different sample of the
same xenograft, suggests that topologically isolated sub-clones
might exist in this case; however, analysis of tumor clonality was
hampered by the fact that estimation of copy number alterations
using the xenograft data was unreliable.
Next, the exome-based mutations and target genes identified
across the adapted models were compared. Intriguingly, 55 of 64
de novo mutations were found to be specific to a single
chemotherapeutic setting. Similarly, 17 of 22 enriched mutations
were specific to a single setting. By contrast, 36 of the 43 completely
or partially depleted mutations (note that a given variant can be
classified as completely or partially depleted in different settings)
were identified in common among the four adapted models
(Fig. 2A; includes functional predictions, see subsequent section).
These data suggest that diverse mutations and genes can potentially
mediate adaptation to chemotherapy.
Functional and prognostic relevance of deleterious
mutations
Deleterious missense mutations were defined as being similarly
predicted by both the SIFT (Sim et al., 2012) and Polyphen-2
(Adzhubei et al., 2013) algorithms. Including frameshift, nonsense
and splice site mutations, ∼60% and ∼70% of the de novo and
enriched mutations, respectively, were considered deleterious. By
contrast, a lower percentage of the completely and partially depleted
missense mutations were considered deleterious (∼50% and ∼40%,
respectively; Fig. 2B). In fact, the proportion of predicted
deleterious mutations in the set of enriched changes was found to
be significantly higher than in the set of partially depleted changes
(Z-score=2.08, P=0.037), further reinforcing the link between
enriched somatic mutations and adaptation to chemotherapies.
Next, we assessed the biological significance of the identified
mutations by examining gene annotations corresponding to Kyoto
Encyclopedia of Genes and Genomes (KEGG) pathways (Kanehisa
et al., 2017). While the set of depleted mutations did not show any
enrichment, the set of acquired (de novo plus enriched) mutations
was found to be over-represented [false discovery rate (FDR) <5%]
in genes belonging to the non-homologous end-joining (NHEJ)
pathway: these genes and their corresponding mutations wereDNTT
Fig. 1. In vivomodeling of adaptation to chemotherapy. (A) Strategy for the
generation of in vivo adapted PDXs. (B) Graphs showing the observed days to
relapse of the PDXs after each cycle of chemotherapy (initial assessment and
four additional cycles).
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(p.Val237Leu) and XRCC6 (p.Val482Cysfs*16) (Table S4). This
observation is consistent with the known role of the NHEJ pathway
(as an error-prone process) in mediating chemoresistance (Jeggo
and Löbrich, 2007).
Following on from the indication of genetic heterogeneity in
adaptation, the prognostic significance of the mutational signatures
identified above was evaluated using somatic data from TCGA
(Cancer Genome Atlas Network, 2012). Thus, TCGA cases were
classified in subsets depending on whether their tumors carried
deleterious mutations in any of the genes from the three sets
described above (i.e. de novo, enriched or depleted mutations/
genes) or were wild-type for all of these genes. In this classification,
Fig. 2. Genes with mutations linked to adaptation to chemotherapies. (A) Venn diagrams showing the number of identified genes with mutations (de novo,
significantly enriched or depleted) across the four chemotherapeutic settings. Italic font marks the number of genes with non-deleterious mutations and
red font indicates the number of genes identified in common. (B) Pie chart showing types of mutations and the number identified in each setting. (C) Kaplan–Meier
curves showing survival rates over time for TCGA patients stratified according to the presence or absence of deleterious mutations in the defined gene sets. The
HR estimations, 95% CIs and log-rank test P-values are shown. (D) GSEA results for the rank of differential gene expression (based on t-statistic) between
TCGAwild-type and mutated (deleterious mutations/genes as defined in the PDXs) patients. Left panel shows results for a significant C2-curated GSEA, which
defines resistance to doxorubicin. Right panel shows the result of the analysis of a set previously associated with homologous recombination defects and
chemoresistance.
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deleterious mutations were defined as being a frameshift, nonsense,
affecting a splice site, or missense predicted to be deleterious by
both SIFT and Polyphen-2 (Table S6). Next, the prognosis of each
TCGA subset was assessed relative to wild-type cases. Thus,
patients whose tumors carried a deleterious mutation corresponding
to the de novo or enriched PDX-derived gene sets tended to have
poorer overall survival, and the combined analysis was significant:
hazard ratio (HR)=2.70, 95% confidence interval (CI) 1.47-4.95,
P=0.004 (Fig. 2C). By contrast, those patients with somatic
missense mutations predicted to be neutral in the de novo and
enriched gene sets did not show a significant difference in
prognosis: HR=1.73, 95% CI 0.89-3.34, P=0.12. The number of
events limited the scope for analysis by cancer subtypes.
Next, the genome-wide expression profiles of the mutated TCGA
subset as defined above were analyzed for their association with
previously proven signatures of chemoresistance. Thus, the mutated
TCGA tumors showed a significant positive correlation (FDR<5%)
with a signature of resistance to doxorubicin (Kang et al., 2004)
(Fig. 2D, left panel). In addition, specific analysis of a signature of
homologous recombination defects and chemoresistance (Peng
et al., 2014) also showed a positive correlation (Fig. 2D, right
panel). Therefore, the proportions of deleterious mutations and their
functional (including co-expression) and prognostic associations
indicate that a relevant portion of the identified genetic alterations
mediate adaptation to chemotherapies.
TCF4 loss mediates chemoresistance
To further evaluate the identified genes, we assessed their
expression correlation with the half maximal inhibitory
concentration (IC50) profiles to cisplatin and olaparib across
hundreds of cancer cell lines (Garnett et al., 2012). Compared to
1000 randomly chosen gene sets of equivalent size, the expression
of genes with deleterious mutations in our study was found to be
enriched in negative correlations with drug responses (Mann–
Whitney test P-values<0.001; Fig. 3A); that is, low expression of
genes identified with deleterious mutations in PDX-based modeling
is frequently associated with higher IC50 values for cisplatin and
olaparib in cancer cell lines, which reinforces their link to
adaptation. Among the identified genes, TCF4 showed the lowest
negative correlation with both IC50 drug profiles [Pearson’s
Fig. 3. TCF4 mediates chemoresistance. (A) Graphs showing the distribution of correlations (PCCs) between the expression of genes with deleterious
mutations (including predicted missense; genes marked in orange) and the IC50 values for cisplatin (left panel) and olaparib (right panel) across cell lines of the
Genomics of Drug Sensitivity dataset. The results for 1000 random sets of genes of equivalent size are shown as gray curves. The threshold of significant (FDR
<5%) negative PCCs is marked in both graphs by a vertical dashed line. (B) shRNA-mediated depletion of TCF4 expression confers resistance to cisplatin,
olaparib and fluorouracil in CAL-51 cells (top panels), and to cisplatin and olaparib in MDA-MB-436 cells (bottom panels; this cell model shows resistance to
fluorouracil at basal conditions). The drug exposures lasted 72 h at the depicted concentrations. ANOVA P-values corrected by multiple testing are shown.
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correlation coefficients (PCCs)=−0.16 and −0.38, respectively,
P-values<0.001]. The cancer cell line dataset did not include
therapeutic results for fluorouracil and lurbinectedin. The TCF4
gene was identified with a common de novo mutation in all of our
four therapeutic assays: c.893C>A (NM_003199) leading to proline
to histidine at position 298 (Fig. S2), which is within a potential TPP
phosphorylation (T297) motif.
Next, we aimed to assess the functional role of TCF4 using breast
cancer cell lines. Two triple-negative cell models were selected for this
study on the basis of their previously defined sensitivity to cisplatin
and olaparib (Lehmann et al., 2011): CAL-51 andMDA-MB-436, the
latter being a BRCA1-mutant model. Using two different short-hairpin
RNA sequences, partial depletion of TCF4 expression led to a
significant increase in the survival of both cell lines when exposed to
cisplatin or olaparib (Fig. 3B). In addition, whilst MDA-MB-436 is
intrinsically resistant to fluorouracil, CAL-51 also showed resistance
to this drug after partial depletion of TCF4 (Fig. 3B). Moreover, the
expression profile of TCF4 in the TCGA dataset was found to be
negatively correlated with multiple pathways of DNA repair (Fig. 4A,
left panels); that is, tumors with low TCF4 expression tend to have
higher expression levels of genes involved in these processes.
Similarly, analysis of the signature of homologous recombination
defects and chemoresistance (Peng et al., 2014) showed a negative
correlation with TCF4 expression (Fig. 4A, right panel).
To further assess the function of TCF4 in a process linked to
chemoresistance, the cell cycle profiles were analyzed. Thus, TCF4
depletion led to a partial bypass of the S and G2/M cell cycle
checkpoints in cisplatin-exposed CAL-51 and MDA-MB-436 cells,
respectively; the population of CAL-51 cells in S phase was reduced
by 8-12% (while G2/M increased by 2-15%) and the population of
MDA-MB-436 cells in G2/M phase was reduced by 50-70%
(Fig. 4B,C). Of note, CAL-51 and MDA-MB-436 differ in TP53
status, the former being wild-type and therefore able to arrest in S
phase (Vogelstein et al., 2000). Analysis of apoptosis and DNA
damage signaling through PARP cleavage and phospho-Ser139
histone H2AX (pH2AX) levels, respectively, was inconclusivewith
regard to specific alterations, with the exception of a relative
increase of pH2AX in TCF4-depleted CAL-51 exposed to cisplatin
(Fig. 4B). Therefore, loss of TCF4 in vitro confers chemoresistance
at least partially by perturbing cell cycle control.
Loss of TCF4 expression post-chemotherapy
To evaluate the above conclusions in a relevant clinical setting, we
analyzed the expression of TCF4 by immunohistochemistry (IHC)
in paired pre- and post-therapy tumor or metastasis samples from
21 breast cancer patients treated with fluoracil-containing
chemotherapies. In this study, the TCF4 immunostaining scores
were found to be significantly lower post-therapy (Wilcoxon
matched-pairs signed-rank test P=0.009; Fig. 5A), further
supporting the link with cancer adaptation to chemotherapy.
Next, to investigate somatic genetic alterations of TCF4, its
coding sequence and splice sites were sequenced in five of the above
post-therapy samples with cancer cell content >70%; whilst many
low-frequency mutations (allele frequency <10%) might appear
post-therapy, one case with relapse after 139 months revealed a
de novo intronic mutation that may affect TCF4 splicing regulation
(c.717+23A>G; Fig. 5B and Table S7). This mutation was
confirmed by Sanger sequencing in two different specimens post-
therapy, but it was absent in two different pre-therapy specimens
and in the germline sample (Fig. 5B). Interestingly, this genomic
position is also a common germline variant, rs1788027, which may
therefore have implications for the therapeutic response of other
individuals. The A-allele associates with lower TCF4 expression in
different human tissues or organs [expression quantitative trait locus
(eQTL) P-values=0.02-0.0001] (GTEx Consortium, 2013).
Analysis of TCGA data confirmed that rs1788027 is an eQTL for
TCF4 in breast tumors (Fig. 5C). Intriguingly, considering the
complete TCGA cohort, the cases with the inferred A/A genotype
revealed a higher proportion of tumor relapses: HR=1.48, 95% CI
1.01-2.17, P=0.047 (Fig. 5D). The study by cancer subtypes
showed similar trends and revealed significance for ER-positive
cases (HR=4.72, 95% CI 1.03-21.59, P=0.045).
Detailed IHC evaluation of the casewith a de novo TCF4mutation
showed loss of expression of the corresponding gene product in the
metastatic lesion post-chemotherapy; in fact, few cells showed
positivity, but were cytoplasmic (Fig. 5E). Of note, normal breast
tissue from healthy individuals shows nuclear positivity of TCF4 in
the luminal-differentiated layer (Fig. 5E, right panel), which is
consistent with its expression from mammary epithelial proliferation
to differentiation (Itahana et al., 2008) and its negative regulatory link
to DNA-binding protein inhibitor ID1 (Parrinello et al., 2001).
DISCUSSION
Understanding the mechanisms of cancer therapeutic resistance is
fundamental to improving cancer care. Themain cause of cancer death
is the appearance of metastases and, most frequently, metastases
develop as a consequence of or in parallel with resistance to therapy.
These observations are probably more relevant for TNBC. Many
studies have shown significant clinical benefit of chemotherapy in the
neoadjuvant, adjuvant and metastatic settings of this cancer subtype
(Joensuu and Gligorov, 2012; Perez et al., 2010). Paradoxically,
TNBC generally shows a better initial response to chemotherapy than
other subtypes (Carey et al., 2007; Liedtke et al., 2008; Rouzier et al.,
2005; vonMinckwitz et al., 2012, 2014; Cortazar et al., 2014;Masuda
et al., 2017). However, pathologic complete responses are only
achieved in 30-40%of early-stage cases and patients who do not show
this response level have 12 times the risk of death (von Minckwitz
et al., 2012). Indeed, fewer than 30% of metastatic cases survive
5 years after diagnosis (Bonotto et al., 2014). In this scenario, while
different therapeutic approaches are being developed and tested, there
is still a need for better understanding of the genetic determinants of
chemoresistance. This study contributes to this understanding by
describing novel mutations and the corresponding genes possibly
mediating chemoresistance.
Our results are consistent with the notion that resistance may be
established through mutations in a variety of genes, which may
present functional interplay but show little overlap for precise gene
identities (Lønning andKnappskog, 2013). The validity of our PDX-
based modeling approach is supported by: (i) observations of
different proportions of deleterious mutations and functional
associations, (ii) analyses of prognosis in human breast cancer
data, and (iii) correlations with therapeutic sensitivity profiles in
cancer cell lines. Detailed examination of gene identities reveals
them to be consistent with expectations (i.e. mutations in DNA-
repair-linked genes DNTT and XRCC6) but also expands on recent
observations: the de novo gene set includes DPYD, whose product
has been implicated in homologous recombination (Someya et al.,
2012), and genetic variation has been associated with fluorouracil
toxicity, which may have further implications for personalized
medicine (Del Re et al., 2017). However, our study design did not
assess the influence of drug holiday (i.e. intermittent treatment) on
the potential reversion of the resistant phenotype or, by extension, on
the role of the identified genes and/or mutations in different settings
of acquisition of resistance and/or adaptation to chemotherapy.
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Guided by the evidence obtained, we assessed the functional
impact of a commonly mutated gene in our modeling study, TCF4.
The corresponding gene product has been implicated in the
regulation of epithelial-mesenchymal transition (Cano and
Portillo, 2010) and is expressed in the progression from
proliferation to differentiation during pregnancy in mammary
gland development (Itahana et al., 2008). In addition, TCF4
physically interacts with the inhibitors of basic helix-loop-helix
(bHLH) transcription factors ID1 and ID2 (Langlands et al., 1997).
While there is no consensus as to the prognostic impact of ID2
expression in breast tumors, relatively high ID1 expression has
consistently been associated with poor prognosis (Lasorella et al.,
2014) and, consequently, with invasive and metastatic capacities
(Fong et al., 2003). In fact, ectopic overexpression of ID1 in
mammary epithelial cells promotes proliferation and invasion, and
TCF4 counteracts these effects (Parrinello et al., 2001). Importantly,
a TCF4 splicing mutation with loss of heterozygosity has recently
been identified in a study of therapy-naïve synchronous metastatic
Fig. 4. TCF4 pathway associations and alteration of cell cycle control. (A) GSEA results for PCCs between TCF4 and any other gene in the TCGA breast
cancer dataset. The left andmiddle panels show the negatively correlated (FDR <5%) pathways linked to DNA repair. Right panel shows the result of the signature
of homologous recombination defects and chemoresistance. (B) Left panels show the cell cycle profiles of control (top) or cisplatin (bottom) CAL-51 cells
transduced with control pLKO.1 or an shRNA targeting TCF4 expression. The percentages of cells in the G1, S and G2/M phases are shown. Right panels so
western blot results for PARP, pH2AX and TUBA (loading control) in the corresponding cell assays. (C) Cell cycle profiles and western blot results for assays of
MDA-MB-436 cells.
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breast cancer (Ng et al., 2017). Thus, based on our results,
metastases with alterations in this gene or protein may further appear
as chemoresistant and less curable.
Cell-based assays confirmed that TCF4 loss mediates
chemoresistance, and immunohistochemical study of tumors
treated with chemotherapies including fluoracil showed consistent
results. The identified de novomutation and the corresponding IHC
results in a given case further suggest that alteration of TCF4
expression mediates chemoresistance and, in turn, indicate the
possible involvement of germline variants in influencing
chemotherapeutic responses. Of note, the study of cisplatin
response in ovarian cancer identified loss of chromosome 18q,
including TCF4, as being associated with resistance (Bosquet et al.,
2014). Nonetheless, studies of larger series with pre- and post-
chemotherapy cancer samples may be warranted to decipher the
precise mechanism by which altered TCF4 function is linked to
chemoresistance. If confirmed, loss of TCF4 could guide the
identification of biomarkers of chemoresistance, based for example
on the analysis of its expression or targets. In parallel, these findings
may emphasize novel therapeutic approaches by combining
chemotherapy with inhibitors of epithelial-mesenchymal
transition and/or ID1 function. Finally, other genes identified in
the study could open up similar opportunities.
MATERIALS AND METHODS
PDX model
The PDX model was derived from a breast cancer patient carrying a
germline BRCA1 mutation and diagnosed at 33 years of age. At diagnosis,
the patient presented a T4 ductal infiltrating triple-negative tumor with
involvement of ipsilateral nodes (N2) and lung metastasis. Primary systemic
Fig. 5. Loss of expression andmutation of TCF4 post-chemotherapy. (A) Graph showing the IHC scores of paired pre- and post-treatment tumors of patients
treated with fluoracil-based therapies. The Wilcoxon matched-pairs signed-rank test P-value is shown. (B) De novo intronic TCF4 mutation in metastasis
post-chemotherapy (pre-treatment and germline results are also shown). (C) Plots of eQTL evaluation between rs1788027 and TCF4 expression in normal breast
tissue [top panel; not significant (n.s.)] or tumors (bottom panel; ANOVA test P-value is shown). (D) Kaplan–Meier curves showing relapse rates over
time for TCGA patients stratified according the genotypes of rs1788027. The HR estimation, 95% CI and log-rank test P-value are shown. (E) IHC results of the
case showing the de novo intronic mutation (left panel, primary tumor; middle panel, metastasis post-treatment) and of normal breast tissue from a healthy woman
(right panel). Arrows mark magnified fields shown in the insets.
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chemotherapy was initiated with TAC regimen for four cycles, followed by
mastectomy to prevent local complications due to extensive breast
involvement. Following surgery, the patient received additional
chemotherapy with the same regimen. Shortly after, brain metastases were
diagnosed and the patient died 8 months post-diagnosis. The primary tumor
specimen was obtained at the Institute of Oncology (ICO), Hospital
Germans Trias i Pujol, Spain and mutational analysis was carried out by the
Molecular Diagnostics Unit (ICO, Hospital Duran i Reynals, Spain) in
compliance with the relevant standards for genetic testing and pathological
determination. The patient provided written informed consent and the study
was approved by the Bellvitge Institute for Biomedical Research (IDIBELL)
Ethics Committee. Non-necrotic tissue pieces from the tumor were selected
and placed in Dulbecco’s modified Eagle medium (BioWhittaker)
supplemented with 10% fetal bovine serum and penicillin/streptomycin at
room temperature. Female athymic (nu/nu) mice (Harlan™) between 4 and
6 weeks of age were used for tumor engraftment into the mammary fat pad.
Tumor growth was monitored two to three times per week, and grown PDXs
were harvested, cut into small fragments and transplanted into additional
animals. The IDIBELL Animal Facility meets Spanish government
regulations and adheres to the Transparency Agreement on Animal
Experimentation promoted by the Confederation of Scientific Societies of
Spain (COSCE), with the collaboration of the European Animal Research
Association (EARA). The facility has obtained accreditation by the
Association for Assessment and Accreditation of Laboratory Animal Care
International. The animals were housed in adequate specific-pathogen-free
(SPF) conditions. Mice were housed in individually ventilated cages on a
12-h light-dark cycle at 21-23°C and 40-60% humidity, and were allowed
free access to an irradiated diet and sterilized water. The study was reviewed
and approved by the IDIBELL Animal Care and Use Committee.
Drugs
Lyophilized lurbinectedin (1 mg vials; PM01183, PhamaMar,Madrid, Spain)
was dissolved in 2 ml of water to a concentration of 0.5 mg/ml and,
subsequently, dissolved in saline for injecting it into the mice. Cisplatin
(1 mg/ml) and fluorouracil (50 mg/ml) solutions for infusion (Ferrer-Farma,
Barcelona, Spain) were obtained from the Pharmacy Unit of the ICO.
Olaparib was purchased dissolved in DMSO (Selleckchem, AZD2881, CAS
number 763113-22-0) and then added to 10% 2-hydroxy-propyl-β-
cyclodextrin/phosphate-buffered saline solution for injecting it into the mice.
Drug-resistant PDX
After three PDX passages, tumor pieces of 2-3 mm3 were implanted in young
femalemice in order to develop paired drug-resistant models. Thus, cisplatin-,
fluorouracil-, lurbinectedin- and olaparib-resistant PDXs were generated by
iterative cycles of in vivo drug exposure, as described previously (Vidal et al.,
2012). Briefly, the PDX from the third passage after initial engraftment was
allowed to grow to a volume of 300-500 mm3 and then exposed to the
corresponding chemotherapeutic regimens. The animals were intravenously
(i.v.) administered with cisplatin with a dose of 3 mg/kg body weight for 3
consecutive weeks (days 0, 7 and 14; cycle #1 of treatment). Post-cisplatin
tumor relapse was harvested, prepared as previously described and engrafted
in additional animals. This process was repeated four times (total of five
cycles of chemotherapy) by treating tumor-bearing mice with stepwise
increasing doses of cisplatin: 3.5, 4 and 5 mg/kg body weight in cycle #2, #3
and #4, respectively. For the rest of the drugs analyzed, the same dose was
used during the iterative cycles: (i) lurbinectedin was i.v. administered once
per week for 3 consecutive weeks (days 0, 7 and 14) at 0.18 mg/kg body
weight diluted in 2-hydroxyl-propyl-β-cyclodextrine; (ii) fluorouracil was
administered by intraperitoneal injection (i.p.) at a dose of 50 mg/kg body
weight (days 0 and 1) at week 1 and 3; and (iii) olaparib was administered
daily during 21 days i.p. at a dose of 50 mg/kg body weight diluted in 10%
2-hydroxyl-propyl-β-cyclodextrine/phosphate-buffered saline. Post-treatment
tumor relapses (defined as tumor volume of 500-750 mm3) were harvested,
prepared as previously described and engrafted in additional animals.
Exome sequencing
The National Centre for Genomic Analysis (CNAG) carried out exome
sequencing by contract. Sequence capture and amplification were performed
using the Agilent SureSelect Human All Exon kit (Agilent) according to the
manufacturer’s instructions. Paired-end sequencing was performed on a
HiSeq2000 instrument (Illumina) using 76 base reads. Reads were aligned
to the reference genome (GRCh37) and BAM files were generated using
SAMtools (Li et al., 2009). Duplicates were removed using SAMtools and
custom scripts, and single-nucleotide variant calling was performed using a
combination of SAMtools and Sidrón algorithms, as described previously
(Puente et al., 2011). For PDX-derived samples, reads were first aligned to
the mouse genome (mm9), and read pairs that did not align to mouse were
then aligned to the human genome following the same pipeline as above.
This procedure removed murine-derived reads, which otherwise could
interfere with the analysis by artificially increasing the number of variants/
mutations. However, this filtering could have led to the removal of certain
human genes with a very high sequence identity to mouse genome, so
relevant chemoresistance-associated mutations may have been missed.
Additional limitations may include poor sequence coverage in other genes.
Common variants, defined as those present in dbSNP135 with a minor allele
frequency >1%, were filtered out. Point mutations were called if they were
covered at least 20-fold and the mutant nucleotide was present in at least two
independent reads. Frameshift mutations were called if the mutant sequence
was present in at least two reads regardless of the coverage of the given
locus. Allele frequency (AF) was determined as the number of mutant reads
divided by the number of total reads.
Deep-targeted sequencing
The 20 PCR products from seven samples were purified using the QIAquick
PCR Purification Kit (Qiagen) and sequencing libraries prepared following
the manufacturer’s recommendations (Illumina). The run was completed
using aMiSeq Reagent Kit V2 in aMiSeq instrument with paired-endmode.
Reads were mapped to the human reference genome using the Burrows–
Wheeler Aligner (Li and Durbin, 2010) and variants extracted using
SAMtools (Li et al., 2009). For differences relative to the reference, only
high-quality bases (Phred score >30) were considered, and per-base error
rate was determined from amplicon positions not affected by mutations or
variation. Those positions detected in a sample at an allele frequency below
the per-base error rate were considered to be below the detection limit. For
small insertions and deletions, the error rate was found to be very low and
total allele frequency is reported if detected (Table S5).
Mutation classification
Mouse sequences and human germline variation were filtered out from the
PDX exome data to identify somatic mutations. Mutations annotated as
synonymous, intronic or untranslated, and in-frame deletion/insertions were
excluded from further analyses. Prediction of the functional impact of
missense mutations was performed using the SIFT (Sim et al., 2012) and
Polyphen-2 (Adzhubei et al., 2013) algorithms. The mutations were
classified as deleterious (including frameshift, nonsense, canonic splice
sites and missense variants predicted to be deleterious by both algorithms)
or non-deleterious (including the remaining missense variants).
Mutation classification relative to chemoresistance
Somatic mutations were further classified as being linked to therapeutic
resistance according to the following criteria:
De novo
Present in a chemotherapy-adapted PDX but completely absent from the
parental PDX (i.e. no detected read at a given position/locus with at least
20-fold coverage).
Completely depleted
Present in the parental PDX but completely absent from a given adapted
model.
In common
Present in both the parental and adapted PDXs, including at low frequency
in either setting (minimum of one read with 20-fold coverage). A Fisher’s
exact test followed by FDR-based correction was used to assess whether
each of the common mutations was significantly enriched or depleted. To
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exclude subtle changes that might not be biologically relevant, only those
mutations that changed (enriched or depleted) with a percentage ≥10%were
considered in further analyses.
Mutation validation
A selection of missense changes predicted to be deleterious, and de novo and
enriched frameshift, nonsense and splice site mutations, underwent Sanger-
based sequencing validation. Primers were designed to amplify the selected
genomic positions while avoiding homologous mouse sequences. To test
human specificity, absence of amplification was confirmed using a mouse-
only DNA sample. The PCR products were treated with ExoSAP-IT
(Affymetrix) and sequenced using the BigDye Terminator v3.1 Cycle
Sequencing kit (Thermo Fisher).
Pathway enrichment analysis
The KEGG dataset of pathway annotations was downloaded from the
corresponding repository (Kanehisa et al., 2017). Statistical significance of
pathway enrichments was assessed using 2×2 contingency tables and
Fisher’s exact test. Values of P<0.05 after FDR-based correction were
considered significant.
Gene expression and survival analyses
For the correlation analysis between basal gene expression and the drug
response across cancer cell lines, data were downloaded from the Genomics
of Drug Sensitivity project (Garnett et al., 2012). This dataset included half
maximal inhibitory concentration (IC50) values for 131 drugs that were
assessed in a panel of 638 human cancer cell lines. Correlations were
computed using the PCC. Pre-processed and normalized data on normal
breast tissue and primary breast tumors were taken from TCGA repository
(Cancer Genome Atlas Network, 2012); somatic mutation and genetic
variation data was obtained following approval by the Data Access
Committee (project #11689). The multivariate Cox regression survival
analyses of somatic mutations (adjusted by age at diagnosis and tumor stage)
included 715 cases with complete data and 67 events. The Gene Set
Analysis (GSEA) (Subramanian et al., 2005) tool was run with default
values for all parameters, using curated (C2) or KEGG gene sets, and a
signature of homologous recombination defects and chemoresistance (Peng
et al., 2014), and the t-statistic or PCC values as rank metric.
Cell culture and antibodies
The CAL-51 and MDA-MB-436 cell lines were cultured in standard
conditions. The cell lines were tested and found to be authentic, and
Mycoplasma contamination was tested periodically. Cellular viability was
evaluated using methylthiazol tetrazolium (MTT)-based assays (Sigma-
Aldrich). TCF4 expression was assessed in western blots using a rabbit
polyclonal antibody: Antibodypedia catalog number ABIN184295. The
expression depletion assays usedMISSION shRNAs (Sigma-Aldrich) catalog
number TRCN0000015036 and TRCN0000015037. The lentiviral
packaging, envelope and plasmids psPAX2, pMD2.G and non-hairpin-
pLKO.1 were purchased from Addgene. Additional antibodies used in this
study were anti-phospho-Ser139 histone H2A.X (2577, Cell Signaling), anti-
PARP (551025, BD Pharmingen) and anti-tubulin-α (ab44928, Abcam). Cell
cycle analysis was performed following a standard protocol of DNA staining
with propidium iodide. Flow cytometry analysis was performed using FACS
Gallios (BD Biosciences) and the ModFit software package.
Tumors treated with chemotherapy
The patient cohort was diagnosed between 1998 and 2013 at the ICO
(Hospital Duran i Reynals, IDIBELL). All patients were treated with a
chemotherapy regimen based on CMF (cyclophosphamide, methotrexate
and fluorouracil) or capecitabine (a pro-drug converted into fluorouracil),
and all patients provided biopsies before treatment and following cancer
progression. Twenty-one cases were included in the study, with a median
age of 49 years (26-71). Eighteen cases had luminal-like tumors, one case
had a triple-negative tumor and two cases had HER2-positive tumors. All
patients received treatment with chemotherapy, one as neoadjuvant setting,
16 as adjuvant therapy after surgery and four as a first line of metastatic
treatment. The median time to progression was 70 months (7-172). The
patients provided informed consent and the study was approved by the
IDIBELL Ethics Committee.
Targeted sequencing
Targeted sequencing of TCF4 was performed by the Quantitative Genomic
Laboratories, Ltd (qGenomics). Briefly, DNA from paraffin-embedded
tumors (pre- and post-chemotherapy paired samples) was extracted
following the FFPE-DNA protocol on a Maxwell robot (Promega),
according to the manufacturer’s instructions. Illumina-compatible libraries
were generated from the extracted DNA with the KAPA HTP library
preparation kit (Roche). Prepared libraries were pooled together and
hybridized against oligonucleotide baits (SeqCap EZ choice, Roche-
NimbleGen) designed to cover the coding and non-coding regions of
TCF4. Enriched pools were paired-end sequenced (2×150 base pairs) on a
NextSeq500 platform (Illumina). Reads were aligned to the human reference
genome with BWA (Li and Durbin, 2010) algorithms, and variant calling,
annotation and filtering was performed by using GATK (McKenna et al.,
2010), ANNOVAR and in-house-developed scripts (available upon request).
Immunohistochemistry
Detection of TCF4 expression in paraffin-embedded tumor samples was
performed using standard immunohistochemical assays with antigen
retrieval achieved in citrate-based buffer. The antibody (H00006925-M03,
Abnova) was used at a dilution of 1:50. The immunohistochemical scores
were defined blindly with respect to patient status and tumor setting by two
independent observers.
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